A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Metastatic Triple-Negative Breast Cancer
Interventions: DRUG: Eribulin|DRUG: SDX-7320|OTHER: Placebo
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: SynDevRx, Inc.